Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target

What caused the Cloudflare global outage? Why did Netherlands suspend Nexperia chipmaker seizure? How will Nvidia earnings impact tech stocks? Why did Target lower profit outlook? What drives Big Tech's increased debt usage? How did Trump’s F-35 plan affect US policy? Why is UK inflation still elevated?

Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target

finance.yahoo.com/news/stifel-maintains-hold-rating-vertex-094515901.html

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock.…

This story appeared on finance.yahoo.com, 2025-11-18 09:45:15.